secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-05-14T18:00:13+00:00
Accession:  0001437749-26-016981
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Therapeutics Q1 2026 net loss $3.9M; NDA on track for mid-2026
----------------------------------------------------------------------

- Net loss $3.9M ($0.46/share) in Q1 2026 vs $2.6M ($0.38/share) in Q1 2025.
- Cash equivalents and investments $137.5M; expects funding through Dec 2027.
- NDA for ALXN1840 (Wilson disease) on track for FDA submission in mid-2026.
- R&D expenses $3.49M, up $1.84M YoY due to contractor/consulting and personnel.
- Presented at AAN; upcoming at EAN (June 27-30) and EASL Congress (May 27-30).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/0001437749-26-016981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/mnpr20260513c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-016981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer